SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application, citing the lack of a statistically significant overall-survival benefit despite strong progression-free-survival results. Traders are reacting to the setback with heavy bearishness, while bulls argue the broader pipeline and upcoming HARMONi-3 data preserve the long-term case and debate whether Summit should challenge the decision.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Traders are focused on the anticipated Phase 3 APPROACH topline readout for Helus Pharmas HLP003, an adjunctive treatment candidate for major depressive disorder. Bulls point to its add-on design and potential for shorter treatment sessions, while skeptics stress the binary risk that Phase 2 efficacy may not hold up in Phase 3 and raise concerns about dilution and competition.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers quarterly results, which beat expectations and came with a higher revenue outlook, are drawing attention; the lower earnings outlook tied to licensing charges and concerns about replacing legacy-drug sales have tempered some bullish reactions.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

Attention centers on the nationwide FAA communications outage, with officials pointing to a router or network issue involving L3Harris while investigators determine whether equipment defects or installation problems were responsible. Traders debate potential contract or liability fallout versus the view that LHX is being made a scapegoat, with some citing the companys strong backlog as a counterpoint.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention as money rotates out of tech and into consumer staples amid defensive positioning, with traders highlighting the sectors sharp rally and fresh highs. Some see pullbacks as buying opportunities, while others warn the move is crowded, overbought, and supported by stretched valuations.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UEC is drawing attention amid a sharp selloff and debate over its latest results: bearish traders point to losses, inconsistent revenue and softer uranium prices, while bulls argue its production ramp, cash-rich balance sheet and long-term nuclear-fuel demand support the investment case. The discussion is split between continued downside concerns and dip-buying around the uranium sectors longer-term prospects.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs positive Phase 2 results for its HER2-targeted drug trastuzumab pamirtecan in recurrent endometrial cancer are drawing attention to its oncology pipeline. Traders are reacting optimistically to the clinical progress, while broader concerns about execution and leadership remain part of the debate.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewys post-earnings selloff is drawing attention despite a raised full-year outlook, with traders focused on sluggish organic growth, flat gross margins and weaker free cash flow. Some view the reaction as excessive given the companys profitability and customer growth, while others see the results and consumer pressures as reasons for continued caution.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,331,579 in circulation. The last known price of Autonomi is 0.03106712 USD and is down -0.55 over the last 24 hours. It is currently trading on 15 active market(s) with $122,300.99 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

The ticker is drawing heavy attention from confusion with Anthropics planned IPO, with many posts using Aragons $ANT.X tag for the AI company; Aragon-focused discussion instead centers on its dissolved project, completed token redemption, and questions about token removal or conversion. The IPO chatter is unrelated to the Aragon crypto asset, and the Aragon posts show no clear new catalyst.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid persistent selling and volatile, weak price action, with traders divided between buying the dip and warning of further declines. Bulls point to Stellars DTCC and real-world-asset tokenization prospects, while skeptics argue that institutional activity has yet to translate into stronger token performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Anglo American (NGLOY) Stock Outpacing Its Basic Materials Peers This Year?

Here is how Anglo American (NGLOY) and Solitario Resources (XPL) have performed compared to their sector so far this year.

Solitario (XPL) Upgraded to Buy: What Does It Mean for the Stock?

Solitario (XPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Mining Sector Rerating: Brownfield Advantage Drives Record Operating Margins in 2026

Mining Sector Rerating: Brownfield Advantage Drives Record Operating Margins in 2026 Mining Sector Rerating: Brownfield Advantage Drives Record Operating Margins in 2026 PR Newswire VANCOUVER, BC...

New Strong Buy Stocks for Oct. 22: XPL, UVE and More

XPL, CTO, MMS, GFI and UVE have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 22, 2025.

Solitario Resources Corp. is a mineral exploration company, which engages in the acquisition and exploration of precious metals and zinc-related exploration mineral properties. Its projects include Florida Canyon in Peru, Lik Zinc in Alaska, Cat Creek Critical Metals project, Bright Angel Copper Gold, and Golden Crest Gold Project. The company was founded on November 15, 1984 and is headquartered in Wheat Ridge, CO.

Solitario Resources Corp

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

XPL News